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1. ABSTRACT  
 Cancer is a dreadful disease being one of the leading causes of death throughout the 
world. It has been estimated that about 8.2 million deaths in 2012 is caused by cancer only. In 
India oral cancer is the most common cancer prevailing among the individuals irrespective of 
their socio-economic status. There are many causes of oral cancer with many complex 
mechanisms of their originality and functionality. Among many mechanisms of cancer 
proliferation, metastasis and their drug resistance capacity, deregulations in the cell death 
mechanism is one. There are three types of cell death machinery and these are apoptosis, 
autophagy and necrosis. The complex interplay of autophagy or apoptosis with tumor cells has 
been reported by many scientists which are rather very confusing and also contradictory form 
one type of cancer to another. In this study there the aim is to find out potential anticancerous 
property in a fruit Terminalia bellerica and its cytotoxic effects on oral cancer cells. Two cell 
lines : FADU and  Hep 2 are taken for the study . Various tests have been performrd in this study 
to detect the apoptotic, autophagic and DNA damaging properties of T. bellerica and the  results 
shows that it has potential anticancerous properties which can inhibit protevtive autophagy and 
promotes apoptosis in Hep 2.  
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2. INTRODUCTION 
Tumor cells are characterized by several hall marks such as limitless growth, not sensitive to 
antigrowth signal,extended angiogenesis,limitless replicative potential,skipping cell death, 
metastasis as well as get rid of immunological surveillance[1].According to the report of 
National Institute of Public Health (Japan) in February 2011, 86% of the world’s oral cancer 
victims reside in India which signifies India is hub of oral cancer[2]. After failuring from various 
chemotherapeutic treatment and drug resistance herbal extract came into focus taking its past use 
as tradicinal medicine. Therefore Terminalia bellerica water extract was taken as an potential 
anticancer weapon specifically in human larynx carcinoma cell line (Hep 2). This  is the first 
report Terminalia bellerica water extract inhibits protective autophagy and augments apoptosis 
in (Hep 2).    
Due to the increasing failure of  chemotherapeutics and antibiotic resitance exhibited by 
pathogenic microbial infectious agents temted to investigate several medicinal due to their active 
components which could combat cancer. Terminalia bellerica Roxb., belongs to family  
‘Combretaceae’ which is a  large deciduous tree commonly found in the   plains and lower hills 
of Southeast Asia. Phytochemical studies explained that T. bellerica contains several  active 
chemical components including, ellagic acid, tannins, gallic acid, 2, 3, 7, 8-tetraoxy-
chromeno[5,4,3-cde]chromene-5,10- dione and  Epigallocatechin gallate [3]. Several 
antiproliferative reports are also available for Terminalia bellerica as it shows cytotoxicity  in 
various cell lines like   Shionogi 115, PC-3,DU-145 , MCF-7. Terminalia bellericais also main  
component of triphala along with Emblica officinalis and Terminalia chebula. Terminalia 
bellerica decreases protective  autophagy in Hep 2 cell line on the contrary apoptosis increases. 
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Therefore an attempt has been made to draw a connecting link between autophagy and apoptosis 
which were induced by Terminalia bellerica water extract in human larynx carcinoma   cell line 
(Hep 2).  
3. REVIEW OF LITERATURE 
3.1. Autophagy 
 Autophagy (type II cell death mechanism) is a highly regulated self-degradative pathway 
in all eukaryotic cells, in which lysosomal degradation of damaged and superfluous cytoplasmic 
components occur, and so, basic biomolecules are produced which are recycled back into the 
cytosol for generation of new macromolecules. These recycled products are also utilized as 
alternative energy sources for the cells undergoing metabolic stress like infection, nutritional 
starvation, hypoxia, and intracellular stress like, piled up damaged prote ins and organelles and 
also during high bioenergetic demands etc, to maintain cellular homeostasis. In tumour cells with 
defective apoptosis, autophagy helps in prolonged survival of the cells. In some cases, defective 
autophagy also induces increased tumorigenesis. Also in some recent studies it has been seen 
that autophagy helps in protecting tumour cells from inflammation due to necrosis and 
alleviating genome damage in cancer cells during metabolic stress. Thus, autophagy is generally 
considered as cell survival mechanism in physiological and pathological conditions such as 
neurodegeneration, myocardiopathy, cancer etc, although it has been proved to regulate apoptotic 
as well as non-apoptotic cell death.  
 The cellular catabolic degradation pathway in autophagy is highly conserved in all 
eukaryotic cells which is executed by autophagy related effectors, many of these known as ATG 
proteins [4, 5]. It is performed in three main steps: nucleation, elongation, and degradation. 
Autophagy begins with formation of an isolation membrane known as phagophore. First a 
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cellular stress inactivates a stress sensor, mTOR (i.e. mammalian target of rapamycin), resulting 
in hypophosphorylation of Atg13. Then with the help of Atg17, this Atg13 binds to Atg1 
(mammalian homolog of Ulk1), which subsequently recruits Atg9. Atg9 extracts lipids from 
various sources to form phagophore [6]. The exact origin of phagophore is controversial; 
however, it is likely derived from the lipid bilayer of ER and/or trans-Golgi and endosomes [7, 
8]. This process is known as vesicle nucleation which is executed by a protein complex. The 
protein complex core comprises of (i) the class III phosphatidylinositol-3-kinase (PI3Kc3 or 
VPS34) which catalyzes phosphorylation of phosphatidylinositol (PI) to phosphatidylinositol 3-
phosphate (PI3P), (ii) the PI3Kc3 regulatory subunit (p150 or Vps15), a myristylated 
serine/threonine kinase which phosphorylates PI3Kc3 and recruits it to the membrane, and (iii) 
the BCL-2 interacting protein, Beclin 1 (the mammalian homolog of yeast ATG6), which likely 
acts as a protein interaction hub [9]. Ambra1, another part of the core complex, acts as a positive 
regulator of autophagy that interacts with Beclin 1 [10]. Further the core complex associates with 
various other proteins that have distinct role in membrane trafficking processes. These proteins 
are ATG14, UVRAG (UV radiation resistance-associated gene), Vmp1 (vacuole membrane 
protein 1), Bif-1 (endophilin B1), and Beclin -1 associated RUN domain containing protein 
(Rubicon) [11, 12]. 
 In the next step, membranes comprising the nascent phagophore get enlarged and then 
fuse at their edges to form multi- layered vesicles known as autophagosomes. Formation of 
autophagosome comprises of two ubiquitin like systems [13]. In one system, Atg 5- Atg 12 
conjugate, where Atg 12 has an ubiquitin like fold,  is formed by two enzymes, Atg 7 ( an E1 
like ubiquitin activating  enzyme), and Atg 10 ( an E2 like ubiquitin carrier protein or enzyme). 
Then Atg5-Atg12 complex non-covalently conjugate with Atg16L dimers to form a 
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multimericAtg5-Atg12-Atg16 complex. The Atg5-Atg12-Atg16L complex seems to associate 
with the extending phagophore to induce curvature into it [14]. In the other system, another 
ubiquitin- like protein, ATG8/LC3 is involved, which is a microtubule-associated protein light 
chain, encoded by the mammalian homologue of Atg8. LC3 is conjugated to 
phosphatidylethanolamine, by the sequential action of ATG4 (a protease), ATG7 (an E1-
likeenzyme), and, ATG3 (an E2- like enzyme). Recruitment and integration of LC3B-II into 
theextending  phagophore is dependent on Atg5–Atg12 conjugate and LC3B-II is found on both 
the internal and external surfaces of the autophagosome, where it plays a role in hemifusion of 
membranes and also in selecting cargo for degradation [14]. 
 After formation of autophagosome, it fuses with lysosome to form autophagolysosome. 
This process involves specific ATG8 paralogs; multiple WD repeat (i.e. tryptophan-aspartic acid 
repeats) domain containing, phosphoinositide- interacting ATG18 paralogs; ATG2A, which binds 
to ATG18; the transmembrane protein, ATG9; SNX18 which causes autophagosometubulation; 
as well as small G-proteins that signal this process. The contents of the autophagosome are 
degraded by lysosomal enzymes inside the autophagolysosome, and after this, the degradation 
products are recycled by the cell [9]. 
 
Role of autophagy at different stages of cancer. 
 Autophagy generally has double-edge role in cancer development [15]. Depending on the 
cell type and stage of tumor development, autophagy may be protective or lethal. In protective 
autophagy, tumor cells undergo enhanced proliferation and metastasis by escaping the 
environmental stresses like anoikis, the first step of metastasis of cancer cells [16] and also in 
other stress conditions like nutrient poor and hypoxic conditions. Protective autophagy maintains 
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TRAIL-resistant phenomena and , altered energy metabolism of tumor cells during tumor 
progression. Tumor cells maintain protective autophagy by activating HIF-α (hypoxia- inducible 
factors) and AMPK (50-AMP-activated protein kinase) in apoptosis deficient (due to mutation in 
the tumor suppressor genes, and/ or oncogenes) and long-term metabolic stress conditions, in a 
fully metastatized cancer [17]. Paradoxically, autophagy-related cell death has been regarded as a 
primary mechanism for tumor suppression during initial stages of cancer development. 
Moreover, autophagy also restricts metastasis of tumor cells at a premature step by restricting 
necrosis and inflammation of developing tumor, thus limiting their invasion and dissemination 
from primary site or the site of their origin. Moreover, lethal (toxic)autophagy brings about the 
release of immunomodulatory factors such as HMGB-1 from dead tumor cells, which triggers 
immune response and restricts metastasis by inhibiting     pro-tumorigenic responses [17]. 
3.2. Apoptosis 
 Apoptosis, or type 1 form of programmed cell death, is another cellular process triggered 
by various strictly conserved cellular signals in healthy individuals. Apoptosis is responsible for 
many biological processes such as normal cell turnover, hormone-dependent atrophy, proper 
development and functioning of the immune system, and embryonic and neural development. So 
in general, it performs as a homeostasis mechanism as well as a defence mechanism. 
Inappropriate apoptosis (either too little or too much) is a contributing factor in many human 
pathophysiological conditions including neurodegenerative diseases, vascular and cardiac 
diseases, autoimmune disorders and many types of cancer. Apoptosis is characterised by several 
cellular changes, like altered nuclear morphology including chromatin condensation and DNA 
fragmentation, minor changes in cytoplasmic organelles, cell shrinkage, plasma membrane 
blebbing, and apoptotic body formation. Apoptosis is triggered by many signals, either in 
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intrinsic/intracellular/mitochondria mediated pathway, or extrinsic/extracellular/receptor 
mediated pathway. Caspases are the executioners of apoptosis which cleave about 400 proteins 
and bring about the morphological changes and death in apoptotic cells [18].  These apoptotic 
caspases are of three types: “initiator caspases” (caspase-2, −8, −9 and −10) that initiate an 
apoptotic cascade and “effector caspases” (caspase-3, −6 and −7) that disassemble the cell, and 
“inflammatory caspases” (caspase-1, -4, -5) [14, 16]. These are controlled by specific cellular 
inhibitors known as inhibitor of apoptotic proteins (IAP), which bind to caspases and inhibit 
them. To overcome the inhibitory effect of IAPs, Smac/DIABLO and HtrA2/Omi are released 
from the mitochondria and bind to or cleave IAPs, respectively [19]. 
Intrinsic pathway:  
 The intrinsic pathway is triggered by various intracellular apoptotic signals like hypoxia, 
oxidative stress, DNA damage, and growth factor deprivation leading to permeabilization of 
outer mitochondrial membrane [20]. This mechanism is regulated by members of Bcl-2 family of 
proteins. In general, the members of the Bcl-2 family have been grouped into 3 classes: the first 
class includes anti-apoptotic BH1234 proteins (e.g. Bcl-2, Bcl-xL, and Mcl-1) which inhibit 
apoptosis; the second class includes pro-apoptotic BH123 proteins which promotes apoptosis 
(e.g. Bax and Bak); and the third divergent class of BH3-only proteins which sense different 
kinds of cell stress/damage, (e.g. Bad and Bid) [21]. The initiation of intracellular signals which 
stimulates the intrinsic pathway may either be in positive or negative fashion. When the cell 
experiences negative signals like deficiency in growth factors, hormones and cytokines, the cell 
fails to suppress death programs and undergoes apoptosis, whereas stimuli like radiation, 
hypoxia, hyperthermia, toxins, free radicals and viral infections act in positive fashion to induce 
apoptosis. This can be explained at molecular level as: in one way, apoptotic signals (in negative 
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fashion) can activate the BH3-only proteins, thereby the antiapoptotic Bcl-2 proteins are 
inactivated. This relieves inhibition of the proapoptotic Bcl-2 proteins and induces apoptosis. In 
contrast, the opposing model (i.e. apoptosis in positive fashion) postulates direct activation of 
pro-apoptotic proteins, Bax and Bak by several BH3-only proteins. The proapoptotic members of 
the Bcl-2 family of proteins enhance the permeability of the mitochondrial outer membrane 
which is known as MOMP (mitochondrial outer membrane permeabilization) [22]. An increase 
in MOMP leads to release of mitochondrial intermebrane protein, including apoptogenic 
molecules such as cytochrome c, to the cytoplasm. In the presence of ATP, cytochrome c binds 
to Apaf-1, i.e. apoptotic protease activating factor-1, and triggers oligomerization. This complex, 
known as an apoptosome, a seven-spoked wheel-shaped complex, recruits and cleaves 
procaspase 9 which gets converted into the active enzyme, caspase 9, which, in turn, activates 
caspase 3, the enzyme that is directly responsible for cell death.  
Extrinsic pathway: 
 The extrinsic apoptotic pathway is activated by trans-membrane receptor mediated 
interaction in which death receptors (DR) present on the cell surface bind to specific apoptotic 
signal transmitting ligands. Such ligands involve soluble molecules of the TNF (tumor necrosis 
factor)  family, which are secreted as homotrimers and bind to members of the TNF-R (TNF-
receptor) family, including TNFR-1, and TRAIL receptors (TNF-α-related apoptosis- inducing 
ligand) DR-4and DR-5, Fas/CD95. When the ligand binds to receptor, the receptor undergoes 
trimerization and subsequent activation [23, 24]. TNF-receptors (TNF-R) possess a death domain 
(DD), which recruits other DD-containing proteins, such as TNF-R type 1-associated death 
domain protein (TRADD) and Fas-associated protein with death domain (FADD). These proteins 
bind to initiator caspases-8 and -10, thus resulting in the homodimerization and then subsequent 
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activation of death- inducing signalling complex (DISC) [25, 26]. After the activation of 
caspases-8 and -10, the caspases-3, -6, and -7 (effector caspases) cleaved, eventually bringing 
cellular degradation and so, induce apoptosis [27].  
3.3. Relation between autophagy and apoptosis in cancer development 
 Two opposite situations may arise due to the intricate interaction between the autophagic 
and apoptotic mechanism. These are, inhibition of autophagy may result apoptosis, and 
suppression of apoptosis may cause autophagy [28, 29, 30]. Alteration in autophagy may have 
differential effects on cancer cells. When autophagy is efficient, it helps in survival of cancer 
cells. When autophagy is inefficient or deregulated, it can induce either apoptotic or non-
apoptotic (necrosis or Programmed cell death type II) to the cancer cell. So, it has been proposed 
by many scientists that, by manipulating autophagy, thus regulating or deregulating the relation 
between autophagy and apoptosis in tumour cells, we can fight cancer.  
3.4. Terminalia bellerica : 
Terminalia bellerica (common name is Baheda in Hindi ,in India) is widely distributed in Sri 
Lanka, India and Nepal, Burma (Myanmar), Indo-China and Thailand, Penninsular Malaysia, 
Sumatra, Java, Borneo (Sabah), the Lesser Sunder Island, central Sulawesi and the Moluccas 
[31]. So, basically the plant is found in south-east Asian countries and is popularly used as 
traditional medicine. Its tremendous medicinal properties are used in Indian ayurvedic medicine. 
Its fruit is commonly used as a part in the medicine ‘Triphalachurna’ in combination with 
Terminalia chebula (Harida), and Emblica officinalis (Amla). 
Phytochemicals  
 Terminalia bellerica  contains the  following phytochemicals: Glucoside (bellericanin) [5, 
32], coloring matter, resins and a greenish yellow oil, Gallo-tannic acid [40], Ellargic acid, gallic 
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acid, lignans(termilignan and thannilignan), 7-hydroxy 3’4’ (methylene dioxy) flavone and 
anolignan B [32]. Tannins, ellargic acid, ethyl gallate, galloyl glucose and chebulaginic acid, 
phenyllemblin, β-sitosterol, mannitol, glucose, fructose and rhamnose [33, 34, 5, 35]. 
 
Classification of Terminalia bellerica(Gaertn.)Roxb.(according to the GBIF Taxonomy 
Hierarchy) [20]  
Kingdom: Plantae 
Phylum Magnoliophyta 
Class Magnoliopsida 
Order Myrtales 
Family Combretaceae 
Genus Terminalia 
Species bellirica 
 
Synonym:Myrobalanusbellirica 
 
Figure 1:  Terminalia bellerica 
 Current studies on the anti-cancer properties of T. Bellerica proves it to be an useful asset 
for preparing a potential anti-cancer drug. In one study, in vitro experiment was carried out to 
know about the anticancer activity of 70% methanolic extract of Terminalia bellerica (TBME) 
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against human breast (MCF-7) carcinoma and human lung (A549) carcinoma and its possible 
mechanism [21]. The extract showed significant cytotoxicity to both A549 and MCF-7 cells, 
whereas, in non-malignant WI-38 cells no cytotoxicity was found. Flow cytometric analysis of 
A549 and MCF-7 was carried out by taking 100 μg/ml of TBME  as the effective concentration 
inducing apoptosis in the cancer cell lines. This concentration of TBME proved to cause DNA 
fragmentation pattern of apoptosis. To know the mechanism of apoptosis induction western 
blotting was performed in which the ratio of Bax/Bcl-2 in both A549 and MCF-7 was found 
increased, which in turn activates the caspase cascade and the cleavage of PARP. These results 
confirmed the anticancer effects TBME in both lung and breast cancer cell lines by modifing the 
Bcl-2 family proteins [21]. 
 Pinmai K et al. (2008) studied the growth inhibitory activities and synergistic effects of 
P. emblicaextract/  doxorubicin or cisplatin and T. Bellerica extract/ doxorubicin or cisplatin 
extracts having certain selective degrees against A549 and HepG2 cells (two cancer cell lines). 
The specific formulation of appropriate dose level of the combinations with significant 
antagonistic effects was different for different cell lines [39]. 
 In another study, the antimutagenic effect of two polyphenolic fractions (TB-3, TB-4) 
isolated from T. bellerica in two strains of S. typhimurium (i.e. TA98 and TA100) against NPD 
(4-nitro-o-phenylenediamine), 2AF (2-aminofluorene) and 4NQNO (4-nitroquinoline-N-oxide) 
has been distinguished [40]. Both the compounds were found to be considerably effective against 
S9-dependent 2AF; rather less striking effect against NPD and almost no effect against 4NQNO 
in TA100 strain. The 13C-NMR spectral analysis, of TB-3 fraction identified it to be a mixture 
of three tannins, and TB-4 was found to have non-tannin fraction. Among many possible 
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mechanisms of the effectiveness of these polyphenols, the ruled out mechanism was the 
interaction between the polyphenols with S9 proteins which has some inhibitory effects [40].  
 It has also been observed that leaf extracts of Terminalia bellerica have considerable  
anticancer compounds with IC50 of  5.65μg/ml [41]. T. bellerica has a variety of phytochemicals 
having various therapeutic applications which have been already reported. Phytochemical studies 
have revealed that Terminalia bellerica contains a variety of bioactive ingredients with reported 
therapeutic activities. Dinesh M.G et al. has reported the dose dependent growth inhibitory 
activity of Methanolic Terminalia Leaf Extracts (MTLE) against cell line Hep G2 cell line. 
MTLE supplementation has down regulated expression of Bcl-2 a potent suppressor of apoptosis 
and induced expression of pro apoptotic proteins Bax, caspase-9 and caspase-3 in a dose 
dependent manner. The researchers also demonstrated that down regulation of the 
Akt/mTORsignaling pathway is responsible for expression of Bax.. The percentage of arrest at 
G2/M phase in Hep G2 cell line increased in comparision to control cell line which. Overall, 
these findings proves that leaves of Terminalia can act as an anti-cancer drug [41].  
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4. OBJECTIVES  
1. Preparationof Terminalia bellerica water extract (TBE). 
2. Detecting the antiproliferative activity of Terminalia bellerica water extract 
3. To check whether TBE induces apoptosis in Hep 2 or not 
4. To check whether TBE induces aautophagy in Hep 2 or not 
5. To check whether TBE induces DNA damage in Hep 2 or not 
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5. MATERIALS AND METHODS 
5.1. Reagents  
3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazoliu (MTT), 4’,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI), dimethylsulfoxide (DMSO), propidium iodide (PI), trypsin, agarose, 
Acridine orange (AO), dihydrorhodamine, Low melting Agarose from Sigma Aldrich, India.  
Fetal bovine serum (sterile- filtered, South American origin), minimal essential medium (MEM), 
antibiotic-antimycotic (100 X ), Lipofectamine 2000® were procured from Invitrogen, India.   
Caspase 3/7 glo kit, from  Promega, India. Other chemicals which were used are of analytical 
grade and high quality.   
5.2. Terminalia bellericawater extract 
 Dry fruits of T. bellerica were purchased  from local market. After that seeds were washed with 
distilled water. Seeds were soaked in Phosphate buffer saline (PBS) (pH-7.4) over night in 40C. 
After that soaked seeds were grinded and centrifuged at 7500 rpm 40C. Pellets were discarded 
and supernatant were filtered by Whatman® fliter followed by 0.22 µ syringe filter. The filtrate 
samples were collected in a round bottom flask and stored in -800C before lyophlization. After 
lyophilisation the powered extract were stored in -200C. Samples were  dissolved for treatment in 
cell lines. 
5.3. Cell lines 
Human squamous carcinoma cell line (FADU), and human larynx carcinoma cell line (Hep 2) 
were cultured in  Minimum Essential Medium supplemented with antibiotic antimycotic(1X) and 
10 % fetal bovine serum. 
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5.4. Cell survibility Assay MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 
diphenyltetrazolium bromide): 
Principle : 
MTT assay  is a colorimetric assay which measures the reduction of yellow coloured       3-(4,5-
dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to purple coloured formazan 
product by the mitochondrial enzyme succinate dehydrogenase. So, when the MTT enters the 
cells and passes into the mitochondria it gets reduced to an insoluble, dark purple coloured 
formazan product only in a live cell. When solubilised by DMSO (an organic solvent), it imparts 
purple coloured with the solubilisation of formazan. Then the absorbance of the solution is 
measured spectrophotometrically at 500- 600 nm. 
Protocol : 
The cells (Hep 2 and FaDu) were  subcultured and when cells reached 80-90% confluency, they 
were trypsinized. The cells were seeded in 96 well plates. After 24 hours, the cells were treated 
with different concentrations of TBE (T. bellerica extract) and incubated for 72 hours. Then 
MTT was added to each well. After 4 hours, the formazan was dissolved with  and the absobance  
was measured at 562nm using micro-plate reader spectrophotometer (Perkin-Elmer) [39]  
 
5.5. DAPI (4’ ,6-Diamidino-2-phenylindole dihydrochloride) staining of Hep 2  
cells 
Principle:  
DAPI is a nucleic acid stain which when binds to the AT rich region in the minor groove of a 
dsDNA possibly due to removal of water molecules from both DAPI and dsDNA. With this 
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reaction DAPI fluoresce blue colour. It basically indicates the chromatin condensation in the 
nucleus due to apoptosis. 
Protocol:  
 
The preseeded cells were treated with different doses of TBE for 24 hr .After that both treated 
and control cells are fixed with 3.7% paraformaldehyde for 20 mints followed by 
permeabilization with 0.1% triton X . Cells were stained with 1µg/ml DAPI for 7 mints. After 
three  times washing with PBS, images were taken in the fluorescence microscope.[40] 
 
5.6. DNA laddering assay:  
Principle:  
 Chromosomal DNA fragmentation is one of the major characteristic of apoptosis. This 
phenomenon is known as DNA laddering. The large number of DNA fragments appearing in 
apoptotic cells results in a multitude of 3'-hydroxyl termini in the DNA. the 3'-hydroxyl ends of 
the fragmented DNA can be labelled with conjugated fluorescein-deoxyuridine triphosphate 
nucleotides (FITC-dUTP) to detect apoptosis in a cell.  
Protocol:  
DNA fragmentation assay by non-enzymatic method was done to detect the presence of 
apoptotic death of cells due to the genotoxic effect of TBE. First, the Hep 2 cells were seeded in 
60 mm petri-plate. Then one petriplate was taken for control, without any TBE treatment and 
other three petri-plates were taken for treatment with different doses of TBE. After 24 h 
incubation, cells were dislodged and pelleted down. Then  followed by addition of100 µl DMSO 
and equal amount of Tris-EDTA buffer (pH) with 2% SDS was added to each of  the cell 
samples and mixed well. Then, the mixture was vortexed for through mixing and then 
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centrifuged at 12,000 rpm at 40C. after this, 40 µl from the resulting supernatant was collected 
and then it was loaded on 1.5% agarose gel on glass slides. Ethidium bromide was used to stain 
the DNA and visualized in BioRad gel documentationsystem using Quantity One software.  
5.7. Caspase activity assay: 
Principle:  
Caspase -3 and -7 are the executioner of apoptosis. In this assay, the reagent which is used 
contains  aproluminiscentcaspase 3/7 substrate having DEVD (a tetrapeptide sequence). DEVD,  
is  optimized for luciferase activity, caspase activity and cell lysis.Thecaspase 3/7 reagent lyses a 
cell and if the cell is in apoptotic stage, then the caspase 3/7 present in the cell cleaves DEVD 
and produces free aminoluciferin. Aminoluciferin is now acted by luciferase and gives a glow 
type luminescent signal. So, luminescence is directly proportional to the caspase activity.  
Protocol: 
Hep 2 cells were seeded in 60 mm plates and TBE were added in various doses , After 24 hr cells 
were scraped and lyzed and centrifuged in 40C at 12000 rpm. After preparing sample caspase 
activities were measured following the manufacturer’s protocol (Promega Corp., Madison, WI) 
[41]. 
 
5.8. Acridine orange staining of Hep 2 cells for detection of autophagy:  
Principle: 
AcridineOrange  is an acidotropic dye used for detection of autophagy. It fluoresces green at 
neutral pH, but when enters acidic vesicles, it gets protonated, accumulated inside the vesicle, 
and gives bright red colour fluorescence. In case of late autophagic vacuoles, it enters the 
autophagolysosome, and becomes protonated, trapped inside it and gives bright red flurescence 
(due to the acidic pH of the autophagolysosome). 
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Protocol: 
Hep 2 cells were cultured  and various doses of TBE were treated for 24 hr. After that cells were  
were treated with 0.5 µg/ml of acridine orange for 15 min  followed by three times washing with  
1X PBS.  Images were captured  in the flurescence microscope. Red intensity were measured in 
Image J software [42]. 
 
5.9. Alkaline COMET Assay: 
Principle :  
Alkaline Comet assay is a very sensitive assay to detect and quantify even small amount of 
dsDNA damage in individual cell. It is also known as single cell gel electrophoresis (SCGE). 
Individual cells are fixed in a thin agarose on a glass slide. From the cell, all the cytoplasmic 
proteins are removed by cell lysing .In alkaline conditions, the DNA unwinds and then this 
unwound DNA is allowed to run in a gel by electrophoretic method. Now, the damaged DNA 
start to migrate from the nucleus from negative to positive pole in the gel cast and form the tail 
part of the comet whereas the intact DNA form the immobilizing head part of the comet. Then 
the DNA is stained with propidium iodide (a DNA specific stain) and observed for the amount of 
red fluroscent in the head, tail and tail length region. The more damage in the DNA the more will 
be the accumulation of DNA at tail region.   
Protocol:  
Hep 2 cells were treated with various  doses of  TBE. TBE treated cells along with the control 
cells were embedded on the slides with gel and the slides were taken for electrophoresis. After 
the TBE treated cells and the control cells were lysed with alkaline  A1 lysis solution  followed 
by  A2 rinse and electrophoresis solution. After electrophoresis was done pictures were captured 
in flurescence microscope. The tail length increase with  increasing dose of TBE. 
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5.10. Determination of reactive oxygen species (ROS) by dihydrorhodamine: 
Principle : 
Dihydrorhodamine 123 is an chemical which can indicate the presence of reactive oxygen 
species (ROS) in a cell. It does not fluoresce when it is uncharged. But when it gets protonated 
by ROS, it fluoresces green light. It can diffuse across the membrane passively and if oxidised to 
cationic rhodamine 123 by ROS, then it gets confined to mitochondria and emits green 
fluorescence. 
Protocol : 
Hep 2 cells were treated with various doses of TBE and after 24 hr cells were treated with2.5 
µg/ml Dihydrorhodamine123 (Dhr123). Then the cells were incubated for 30 mint. After that 
cells were washed three times with 1X PBS and pictures were captured in flurescence 
microscope. The green intensity increases with increasing reactive oxygen species [43]. 
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6. RESULT AND DISCUSSION 
6.1. Cell viability assay (MTT Assay):  
MTT assay was performed to check the viability of two different oral cancer cell lines: FaDu and 
Hep 2  at different concentrations of TBE. 
 
Fig- 2 : Graph showing MTT assay of FaDu and Hep 2 cell lines 
Inference: 
It was observed that, the cell survivability is decreasing with increase in the concentration of 
TBE in both the cell lines. The significant concentrations of TBE (the star marked conc. on the 
graph)at which cell viability is significantly decreasing  are  1mg/ml, 0.5mg/ml, and 0.25mg/ml. 
The graph of MTT assay shows that the TBE has cytotoxic effects on both FaDu, and Hep 2, but 
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Hep 2 is comparatively more susceptible to decreased cell viability than FaDu at same 
concentrations. 
6.2. DAPI staining  
DAPI staining of control and TBE treated of Hep 2cellss was performed to detect nuclear 
membrane bebbling which is a distinguished characteristics of apoptotic cell death.  
 
Fig-3: DAPI staining of Hep 2 cells treated without and with different concentrations of 
TBE. 
Inference : 
From the above figure, significant increase in the nuclear membrane bebbling can be demarked 
in a dose dependent manner. So, it confirms about the apoptotic cell death of Hep 2 cells is 
0.1   mg/ml 
TBE 
0.5  mg/ml  TBE 1  mg/ml 
TBE 
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increasing with increased nuclear membrane blebbing and DNA damage with increase in dose of 
with increasing dose of TBE.  
6.3.  DNA laddering test: 
In DNA laddering test, the aim was to detect the fragmentation of DNA, a marked characteristics 
of apoptosis due to effects of TBE. 
 
Fig-4: The gel elctrophoresis shows bands of fragmented DNA of control and TBE treated 
Hep 2 cells in different lanes 
Inference: From gel electrophoretic analysis, it was observed that, the number of DNA bands 
are increasing with increase in the concentration of the TBE in Hep 2 cells.  
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6.4. Caspase 3/7 glo assay:   
Caspase 3/7 glo assay was performed to detect the caspase activity of TBE treated Hep 2 cells in 
comparision to control cells.  
Table-2: Caspase 3/7 activity of Hep 2 cells when treated with di fferent concentrations of TBE 
Conc. of TBE  
(in mg/ml) 
Caspase 3/7 activity (in terms of 
luminescence of the TBE treated cells) 
Control 2096 
0.1 3291 
0.5 4429 
1 7924 
 
 
Fig- 5: Graph showing caspase 3/7 activity of TBE treated Hep 2 cell 
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Inference:  
It can be inferred from this graph that, with increase in the concentration of TBE, the cells show 
increased caspase 3/7 activity which ultimately proves that apoptotic activity is increasing in a 
dose dependent manner. 
6.5. Acridine orange staining:  
Acridine orange staining was performed to see whether the presence of autophagy or not in the 
TBE treated Hep 2 cells. 
 
Fig-6: Acridine orange staining of control and TBE treated Hep 2 cells  
0.1  mg/ml TBE 
1   mg/ml TBE 
Control 
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Inference: From the above figures, it can be seen that intensity of red colour is decreasing which 
indicates decrease in autophagic vacuole or late autophagosomes in TBE treated cells with 
increase in the concentration of TBE dose whereas the microscopic observationof the cells 
showed the increase in nonviable cells with increase in TBE dose treatment. So, interestingly, it 
can be inferred that there was previousely protective autophagy machinery employed by the Hep 
2 cells for their survival, proliferation and metastasis, but TBE inhibits protective autophagy in 
the Hep 2 cells. 6.6. Comet assay : 
 Comet assay was performed to detect dsDNA damagein Hep 2 cells when treated with TBE. 
 
 
Fig- 7: The head and tail moment of a comet due to the effect of TBE 
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Inference :  
The increase in tail length and more accumulation or more intensity at the tail region conforms 
the DNA damage in Hep 2 cells with increase in the dose of TBE. 
6.7. Determination of reactive oxygen species (ROS) by dihydrorhodamine: 
To detect the ROS activity of different concentration of TBE treated Hep 2  cells and to detect 
ROS mediated Apoptosis in the cells, the cells treated with different concentrations of TBE were 
treated with dihydrorhodamine 123 and the results were seen under fluorescent microscope.  
Inference:  
The increasing trend of green intensity from control to TBE treated cells shows that after TBE 
treatment, the cells possibly undergo ROS mediated apoptosis. Production of ROS increases with 
increase in the dose of TBE (Fig -8 ). 
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Fig-8 : Treatment of Hep 2 cells with dihydrorhodamine to detect ROS mediated apoptosis 
  So, in summary it can be predicted that, an active molecule in the TBE plays a 
significant role in inhibiting protective autophagy (from Acridine orange staining staining 
results) and induces apoptosis (from ROS test, DAPI staining, Caspase 3/7 glo assay,  Comet 
assay, DNA laddering test) in Hep 2 cells, thus inhibiting the unabated proliferation of the cancer 
cells (Hep 2).  
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7. CONCLUSION  
It has remained fascinating for scientists to eliminate tumors by manipulating autophagy [47]. 
Inhibiting or promoting autophagy therapeutically for cancer treatment will be a great approach 
to anticancer drug development. The molecular interplay between autophagy and cancer is also a 
less studied discipline for cancer therapy.  The mechanism of regulation or deregulation o f 
autophagy in cancer is different in different types of cancer cases. For example, in the anti-
angiogenesis therapy, the main reason behind its failure is that, cancer cells trigger autophagy in 
response to hypoxia after this therapy and tend to survive [48]. In this case if autophagy is 
inhibitited along with the administration of anti-angiogenic drug, then recurrence of cancer can 
be checked. In another case, activation of autophagy can be effective in cancer treatment, such 
as, the TNBC (triple negative breast cancer) derived cell lines are reported to have decreased cell 
viability when these are treated with mTOR pathway inhibitor, so that, inhibitio n of autophagy 
gets released [49]. Another thing is to deeply understand the relationship between the two  
programmed cell death mechanisms: autophagy and apoptosis in cancer development. In some 
cases, one of them is inhibited, another is induced, or both are induced, or both are suppressed, or 
one is independent of the other and vice versa. No doubt, extensive research in this regard can 
make way for highly effective cancer therapy, however, we are at the initial stage of such a huge 
success in the present scenario.  
8. FUTURE ASPECTS 
The future aspects of this study can bring a potential anti-cancer drug from a very cheap plant 
product which is already very popular among Indians. So many things are to be investigated for 
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an anticancer drug from T. bellerica. First, the active compounds in TBE are to be isolated and 
characterized which is responsible for anticancer property in oral cancer cells. Then, its role in 
crosslinking apoptosis and autophagy in cancer suppression is to be found out. And also the 
effective drug delivery pathway for T. bellerica is to be validated. If really, it will be proved that 
the fruit Terminalia bellerica has highly significant role in oral cancer treatment, then it will be a 
nice discovery in medical science for development of a cheap but effective anti-cancer medicine. 
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